SEC Form 4 · accession 0001225208-17-014467
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maulik Nanavaty
Officer — SVP & Pres, Neuromodulation
Period of report
Aug 30, 2017
Accepted (ET)
Sep 1, 2017 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 30, 2017 | M | 10,000 | $12.52 | A | 218,233 | D | |
| Common StockF1 | Aug 30, 2017 | M | 10,000 | $7.41 | A | 228,233 | D | |
| Common StockF1 | Aug 30, 2017 | M | 7,031 | $6.28 | A | 235,264 | D | |
| Common StockF2,F1 | Aug 30, 2017 | S | 27,031 | $27.0831 | D | 208,233 | D | |
| Common StockF1 | Aug 31, 2017 | M | 20,000 | $7.41 | A | 228,233 | D | |
| Common StockF1 | Aug 31, 2017 | M | 10,000 | $7.39 | A | 238,233 | D | |
| Common StockF3,F1 | Aug 31, 2017 | S | 30,000 | $27.4513 | D | 208,233 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $12.52 | Aug 30, 2017 | M | 10,000 | D | — | Feb 12, 2018 | Common Stock | 10,000 | 15,568 | D |
| Stock Option (Right to Buy)F5 | $7.41 | Aug 30, 2017 | M | 10,000 | D | — | Feb 16, 2020 | Common Stock | 10,000 | 38,231 | D |
| Stock Option (Right to Buy)F6 | $6.28 | Aug 30, 2017 | M | 7,031 | D | — | Feb 27, 2022 | Common Stock | 7,031 | 0 | D |
| Stock Option (Right to Buy)F5 | $7.41 | Aug 31, 2017 | M | 20,000 | D | — | Feb 16, 2020 | Common Stock | 20,000 | 18,231 | D |
| Stock Option (Right to Buy)F7 | $7.39 | Aug 31, 2017 | M | 10,000 | D | — | Feb 28, 2023 | Common Stock | 10,000 | 34,035 | D |
Explanation of responses
- F1Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at $27.08 and $27.09. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $27.45 to $27.465, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Grant to the reporting person of an option to purchase 25,568 shares of common stock vesting in four annual increments beginning on February 12, 2009, the first anniversary of the grant.
- F5Grant to the reporting person of an option to purchase 48,231 shares of common stock vesting in four annual increments beginning on February 16, 2011, the first anniversary of the grant.
- F6Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.
- F7Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.